Pages that link to "Q55038613"
Jump to navigation
Jump to search
The following pages link to Serum free light chains for monitoring multiple myeloma. (Q55038613):
Displaying 50 items.
- Appraisal of immunoglobulin free light chain as a marker of response (Q24624398) (← links)
- Characterization of a unique conformational epitope on free immunoglobulin kappa light chains that is recognized by an antibody with therapeutic potential (Q34175984) (← links)
- International uniform response criteria for multiple myeloma. (Q34549410) (← links)
- Prognostic value of serum free light chain ratio at diagnosis in multiple myeloma (Q34615704) (← links)
- Monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, and curcumin: a randomized, double-blind placebo-controlled cross-over 4g study and an open-label 8g extension study (Q34637209) (← links)
- Immunoglobulin light chains activate nuclear factor-κB in renal epithelial cells through a Src-dependent mechanism (Q34666924) (← links)
- The evolving use of serum free light chain assays in haematology (Q34758218) (← links)
- International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders (Q34884527) (← links)
- Immunoglobulin light chains activate tubular epithelial cells through redox signaling. (Q35153211) (← links)
- Differential effects of cyclophosphamide and mycophenolate mofetil on cellular and serological parameters in patients with systemic lupus erythematosus (Q35577284) (← links)
- Serum N-Glycans: A New Diagnostic Biomarker for Light Chain Multiple Myeloma (Q35663623) (← links)
- The anion gap and routine serum protein measurements in monoclonal gammopathies (Q35664630) (← links)
- The Association between Polyclonal Combined Serum Free Light Chain Concentration and Mortality in Individuals with Early Chronic Kidney Disease (Q35680192) (← links)
- Novel renal replacement strategies for the elimination of serum free light chains in patients with kappa light chain nephropathy (Q35959002) (← links)
- The pathogenesis and diagnosis of acute kidney injury in multiple myeloma (Q36033448) (← links)
- Utility of serum free light chain measurements in multiple myeloma patients not achieving complete response to therapy (Q36137449) (← links)
- Bortezomib, thalidomide and dexamethasone, with or without cyclophosphamide, for patients with previously untreated multiple myeloma: 5-year follow-up. (Q36592788) (← links)
- Atypical serum immunofixation patterns frequently emerge in immunomodulatory therapy and are associated with a high degree of response in multiple myeloma (Q36766519) (← links)
- Management of paraproteinaemia (Q36778432) (← links)
- Immunodiagnostic capabilities of anti-free immunoglobulin light chain monoclonal antibodies (Q37050005) (← links)
- Serum free light chain analysis in multiple myeloma and plasma cell dyscrasias (Q37821496) (← links)
- Guidelines for the diagnosis and management of multiple myeloma 2011 (Q37875193) (← links)
- Novel approaches for reducing free light chains in patients with myeloma kidney. (Q37986358) (← links)
- The serological diagnostic challenges of multiple myeloma (Q38351789) (← links)
- Comparison of serum free light chain and urine electrophoresis for the detection of the light chain component of monoclonal immunoglobulins in light chain and intact immunoglobulin multiple myeloma (Q38398899) (← links)
- MDX-1097 induces antibody-dependent cellular cytotoxicity against kappa multiple myeloma cells and its activity is augmented by lenalidomide (Q38912820) (← links)
- Formation of assemblies on cell membranes by secreted proteins: molecular studies of free λ light chain aggregates found on the surface of myeloma cells (Q39131174) (← links)
- Serum free light-chain assay for the detection and monitoring of multiple myeloma and related conditions (Q39932145) (← links)
- Overexpression of carboxylesterase-2 results in enhanced efficacy of topoisomerase I inhibitor, irinotecan (CPT-11), for multiple myeloma (Q39943302) (← links)
- The spot urine protein/creatinine ratio is a simple, rapid and inexpensive method for monitoring patients with light-chain multiple myeloma (Q40332106) (← links)
- Early Prognostic Value of Monitoring Serum Free Light Chain in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation (Q40368431) (← links)
- The association of serum-free light-chain levels with markers of renal function (Q40855551) (← links)
- Combined use of free light chain and heavy/light chain ratios allow diagnosis and monitoring of patients with monoclonal gammopathies: Experience of a single institute, with three exemplar case reports (Q41195228) (← links)
- Pivotal Role of Apoptosis Signal-Regulating Kinase 1 in Monoclonal Free Light Chain–Mediated Apoptosis (Q42138391) (← links)
- Role of serum free light chain assay in the detection of early relapse and prediction of prognosis after relapse in multiple myeloma patients treated upfront with novel agents (Q42361980) (← links)
- Sensitivity of serum free light chain measurement of residual disease in multiple myeloma patients (Q43064468) (← links)
- Detection of kappa and lambda light chain monoclonal proteins in human serum: automated immunoassay versus immunofixation electrophoresis (Q43233905) (← links)
- Normalization of free light chain kappa/lambda ratio is a robust prognostic indicator of favorable outcome in patients with multiple myeloma (Q44558771) (← links)
- Further stratification of patients with multiple myeloma by International Staging System in combination with ratio of serum free κ to λ light chains (Q44944338) (← links)
- Aggressive relapse of multiple myeloma with intracerebral extension and associated hemorrhage (Q48132077) (← links)
- Use of serum free light chain analysis and urine protein electrophoresis for detection of monoclonal gammopathies. (Q51645966) (← links)
- Prognostic impact of immunophenotypic complete response in patients with multiple myeloma achieving better than complete response. (Q52889189) (← links)
- Guidelines on the diagnosis and management of multiple myeloma 2005. (Q53556535) (← links)
- Prognostic impact of serial measurements of serum-free light chain assay throughout the course of newly diagnosed multiple myeloma treated with bortezomib-based regimens (Q56963837) (← links)
- Prognostic utility of serum free light chain ratios and heavy-light chain ratios in multiple myeloma in three PETHEMA/GEM phase III clinical trials (Q58760132) (← links)
- Outcome of autologous stem cell transplantation for AL amyloidosis in the UK (Q58853185) (← links)
- Serial serum free light chain measurements do not detect changes in disease status earlier than electrophoretic M-spike measurements in patients with intact immunoglobulin myeloma (Q82819483) (← links)
- The Role of Serum Immunoglobulin Free Light Chain in Response and Progression in Waldenstrom Macroglobulinemia (Q83638689) (← links)
- The Level of Minimal Residual Disease in the Bone Marrow of Patients with Multiple Myeloma before High-Dose Therapy and Autologous Blood Stem Cell Transplantation Is an Independent Predictive Parameter (Q84538476) (← links)
- An infrequent relapse of multiple myeloma predominantly manifesting as light chain escape: clinical experience from two Chinese centers (Q85039052) (← links)